SG Americas Securities LLC Purchases 49,492 Shares of Glaukos Corporation $GKOS

Key Points

• SG Americas Securities dramatically increased its stake in Glaukos, buying 49,492 shares in Q4 to hold 60,232 shares worth about $6.8 million, while institutional investors now own roughly 99.04% of the stock.
• Significant insider selling occurred last quarter — CEO Thomas Burns sold 186,945 shares for about $21.5 million and insiders sold 324,657 shares totaling $37.7 million, leaving insiders with 6.40% ownership.
• Glaukos reported Q4 revenue of $143.12 million (up 35.6% year-over-year) but missed on EPS (‑$0.28 vs. consensus ‑$0.22), and analysts remain generally positive with a consensus rating of Moderate Buy and an average price target of $133.69.

SG Americas Securities LLC boosted its position in shares of Glaukos Corporation (NYSE:GKOS - Free Report) by 460.8% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 60,232 shares of the medical instruments supplier's stock after purchasing an additional 49,492 shares during the quarter. SG Americas Securities LLC owned about 0.10% of Glaukos worth $6,801,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Assenagon Asset Management S.A. grew its position in shares of Glaukos by 15.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 182,393 shares of the medical instruments supplier's stock worth $20,594,000 after buying an additional 24,848 shares in the last quarter. Diversified Trust Co. lifted its stake in Glaukos by 72.6% in the fourth quarter. Diversified Trust Co. now owns 7,252 shares of the medical instruments supplier's stock worth $819,000 after acquiring an additional 3,050 shares during the period. Swiss Life Asset Management Ltd purchased a new stake in Glaukos in the third quarter worth about $209,000. JPMorgan Chase & Co. grew its holdings in Glaukos by 4.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 670,083 shares of the medical instruments supplier's stock worth $54,645,000 after acquiring an additional 27,646 shares in the last quarter. Finally, CIBC Bancorp USA Inc. bought a new position in Glaukos during the 3rd quarter worth about $486,000. 99.04% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Glaukos news, CEO Thomas William Burns sold 186,945 shares of the firm's stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $115.00, for a total transaction of $21,498,675.00. Following the completion of the transaction, the chief executive officer directly owned 153,775 shares of the company's stock, valued at approximately $17,684,125. This trade represents a 54.87% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Aimee S. Weisner sold 15,000 shares of Glaukos stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $117.38, for a total transaction of $1,760,700.00. Following the sale, the director owned 18,806 shares of the company's stock, valued at approximately $2,207,448.28. The trade was a 44.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 324,657 shares of company stock worth $37,692,269 in the last quarter. 6.40% of the stock is currently owned by corporate insiders.

Glaukos Stock Performance

Shares of GKOS stock opened at $107.68 on Wednesday. The business has a fifty day moving average of $112.31 and a 200 day moving average of $102.37. Glaukos Corporation has a 1 year low of $73.16 and a 1 year high of $130.23. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.69 and a quick ratio of 4.06. The firm has a market capitalization of $6.25 billion, a price-to-earnings ratio of -33.03 and a beta of 0.70.

Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings data on Tuesday, February 17th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.06). Glaukos had a negative net margin of 36.99% and a negative return on equity of 7.00%. The firm had revenue of $143.12 million during the quarter, compared to analyst estimates of $132.16 million. During the same period in the prior year, the company posted ($0.40) earnings per share. The firm's revenue for the quarter was up 35.6% on a year-over-year basis. As a group, research analysts expect that Glaukos Corporation will post -1.08 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently commented on GKOS. Citigroup boosted their price target on shares of Glaukos from $113.00 to $125.00 and gave the company a "buy" rating in a report on Thursday, December 11th. BTIG Research reissued a "buy" rating and set a $131.00 price objective on shares of Glaukos in a report on Wednesday, February 18th. Piper Sandler reissued an "overweight" rating and issued a $165.00 price objective on shares of Glaukos in a research note on Wednesday, January 14th. Stephens upped their target price on Glaukos from $115.00 to $145.00 and gave the stock an "overweight" rating in a report on Friday, January 2nd. Finally, The Goldman Sachs Group reaffirmed a "buy" rating and set a $138.00 target price on shares of Glaukos in a research report on Friday, January 9th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $133.69.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company's core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos's flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.

Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corporation (NYSE:GKOS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.